Clinical Trials Logo
  1. Home
  2. Other
  3. NCT03212586

BAY 1902607: Single Dose Escalation, Safety and Tolerability, Pharmacokinetics, Bioavailability, Food Effect

Clinical Trials, Phase I as Topic Clinical Trial

Official title:
Randomized, Placebo-controlled, Double-blind, Parallel-group Study to Investigate the Safety, Tolerability and Pharmacokinetics of Increasing Single Oral Doses of BAY1902607 Including the Relative Bioavailability Between Different Pharmaceutical Formulations and the Effect of Food on the Pharmacokinetics of BAY1902607 in Healthy Men

Clinical Trial Summary

This study is a first-in-man study that will investigate the safety, tolerability and pharmacokinetics of ascending single doses of BAY1902607 using a placebo controlled, randomized, single center design. In addition the influence of food on the pharmacokinetics of BAY1902607 and the bioavailability between different pharmaceutical formulations will be investigated

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

  • Clinical Trials, Phase I as Topic
Clinical Trial Details
NCT number NCT03212586
Study type Interventional
Source Bayer
Contact
Status Completed
Phase Phase 1
Start date July 18, 2017
Completion date July 27, 2018
View Details
See also
  Status Clinical Trial Phase
Completed NCT02212080 - First in Human Study in Healthy Volunteers to Investigate the Safety, Tolerability and Pharmacokinetics of BAY1214784 Phase 1
Completed NCT02817100 - First in Human Study to Investigate the Safety and Tolerability, Pharmacokinetics, Itraconazole Drug-drug-interaction and Food Effect of BAY1817080 Phase 1